StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)

Stock analysts at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

The stock’s 50-day moving average price is $0.14 and its 200-day moving average price is $0.61. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The company has a market capitalization of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85.

Institutional Trading of Nabriva Therapeutics

A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 795,938 shares of the biotechnology company’s stock after buying an additional 402,144 shares during the period. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.27% of the stock is currently owned by hedge funds and other institutional investors.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.